(Q67661545)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Prostate-specific antigen: Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker (English)

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

31 October 2022

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

31 October 2022

author name string

G. S. Dundas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1693877

31 October 2022

A. T. Porter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1693877

31 October 2022

P. M. Venner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1693877

31 October 2022

language of work or name

English

0 references

publication date

1 July 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

16 September 2019

number of pages

4

1 reference

based on heuristic

inferred from page(s)

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

31 October 2022

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

31 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

45-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

Carcinoma of the prostate: pathology, staging, and treatment

16 September 2019

cites work

1

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Observations on surgical management of carcinoma of prostate with limited nodal metastases

31 October 2022

2

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06

31 October 2022

3

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prostatic acid phosphatase: its current clinical status

31 October 2022

5

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer

31 October 2022

6

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase

31 October 2022

7

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer

31 October 2022

8

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prostate-specific antigen. Superior serum marker for prostatic carcinoma

31 October 2022

9

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

31 October 2022

10

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

31 October 2022

11

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

31 October 2022

12

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

What's new in tumor markers for prostate cancer?

31 October 2022

13

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Serum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course

31 October 2022

15

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

31 October 2022

17

1 reference

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

https://api.crossref.org/works/10.1002/1097-0142(19900701)66:1%3C45::AID-CNCR2820660110%3E3.0.CO;2-G

31 October 2022

Identifiers

10.1002/1097-0142(19900701)66:1<45::AID-CNCR2820660110>3.0.CO;2-G

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1693877%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference